GENFIT/$GNFT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GENFIT
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Ticker
$GNFT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
180
ISIN
US3722791098
Website
GENFIT Metrics
BasicAdvanced
$193M
102.66
$0.04
1.07
-
Price and volume
Market cap
$193M
Beta
1.07
52-week high
$6.24
52-week low
$2.55
Average daily volume
4.5K
Financial strength
Current ratio
1.234
Quick ratio
1.189
Long term debt to equity
8.02
Total debt to equity
89.756
Interest coverage (TTM)
0.69%
Profitability
EBITDA (TTM)
5.868
Gross margin (TTM)
100.00%
Net profit margin (TTM)
2.12%
Operating margin (TTM)
4.63%
Effective tax rate (TTM)
18.41%
Revenue per employee (TTM)
$457,130
Management effectiveness
Return on assets (TTM)
1.26%
Return on equity (TTM)
2.20%
Valuation
Price to earnings (TTM)
102.66
Price to revenue (TTM)
2.168
Price to book
2.42
Price to tangible book (TTM)
7.75
Price to free cash flow (TTM)
10.517
Free cash flow yield (TTM)
9.51%
Free cash flow per share (TTM)
34.32%
Growth
Revenue change (TTM)
105.72%
Earnings per share change (TTM)
-105.16%
3-year revenue growth (CAGR)
-6.09%
10-year revenue growth (CAGR)
26.65%
3-year earnings per share growth (CAGR)
-71.00%
10-year earnings per share growth (CAGR)
-27.65%
What the Analysts think about GENFIT
Analyst ratings (Buy, Hold, Sell) for GENFIT stock.
GENFIT Financial Performance
Revenues and expenses
GENFIT Earnings Performance
Company profitability
GENFIT News
AllArticlesVideos
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
GlobeNewsWire·2 weeks ago
GENFIT Reports First Quarter 2025 Financial Information
GlobeNewsWire·1 month ago
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GENFIT stock?
GENFIT (GNFT) has a market cap of $193M as of June 30, 2025.
What is the P/E ratio for GENFIT stock?
The price to earnings (P/E) ratio for GENFIT (GNFT) stock is 102.66 as of June 30, 2025.
Does GENFIT stock pay dividends?
No, GENFIT (GNFT) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next GENFIT dividend payment date?
GENFIT (GNFT) stock does not pay dividends to its shareholders.
What is the beta indicator for GENFIT?
GENFIT (GNFT) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.